An immediate, allergic skin reaction to aprotinin after reexposure to fibrin sealant
| Autor: | C. Braun, A.M. Scheule, R. Schosser, G. Antoniadis, W. Beierlein |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
medicine.medical_specialty
Allergy Time Factors Immunology Fluorescent Antibody Technique Enzyme-Linked Immunosorbent Assay Fibrin Tissue Adhesive Immunoglobulin E Fibrin Dermatitis Atopic Immunoenzyme Techniques Aprotinin Antibody Specificity medicine Humans Immunology and Allergy Adverse effect biology Fibrin sealants business.industry Sealant Hematology Exanthema Middle Aged medicine.disease Dermatology Antibodies Anti-Idiotypic biology.protein Female business Allergic skin reaction medicine.drug |
| Zdroj: | Transfusion. 40:302-305 |
| ISSN: | 1537-2995 0041-1132 |
| DOI: | 10.1046/j.1537-2995.2000.40030302.x |
| Popis: | BACKGROUND: The safety of fibrin tissue adhesives has been a concern since they entered wide clinical application. Most commercially available kits contain the proteolytic inhibitor, aprotinin, to stabilize the fibrin clot. A bovine protein, this substance has an allergenic potency. CASE REPORT: This case report presents a patient who had a generalized allergic skin reaction, probably triggered by aprotinin upon reexposure to fibrin sealant injected subgaleally to achieve closure of a liquor fistula after neurosurgical treatment. The serologic investigation revealed aprotinin-specific IgE and IgG. From 1990 through 1998, reports of five allergic reactions following 1 million exposures to fibrin sealant were made to the manufacturer. The clinical relevance of allergic reactions to aprotinin contained in fibrin sealants and measures to avoid them are discussed. CONCLUSION: These hypersensitivity reactions are extremely rare (incidence, 0.5/100,000 for all reactions and 0.3/100,000 for serious reactions), but they must be kept in mind as possible adverse events after repeated applications of fibrin sealants within a few weeks. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text